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Background: Polycystic ovary syndrome (PCOS) affects between 2% and 26% of reproductive-
age women in the UK, and accounts for up to 75% of anovulatory infertility. The major symp-
toms include ovarian disruption, hyperandrogenism, insulin resistance, and polycystic ovaries. 
Interestingly, at least half of the women with PCOS are obese, with the excess weight playing 
a pathogenic role in the development and progress of the syndrome. The first-line treatment 
option for overweight/obese women with PCOS is diet and lifestyle interventions; however, 
optimal dietary guidelines are missing. Although many different dietary approaches have been 
investigated, data on the effectiveness of very low-calorie diets on PCOS are very limited.
Materials and methods: The aim of this paper was to investigate how overweight/obese 
women with PCOS responded to LighterLife Total, a commercial very low-calorie diet, in 
conjunction with group behavioral change sessions when compared to women without PCOS 
(non-PCOS).
Results: PCOS (n=508) and non-PCOS (n=508) participants were matched for age (age ±1 
unit) and body mass index (body mass index ±1 unit). A 12-week completers analysis showed 
that the total weight loss did not differ significantly between PCOS (n=137) and non-PCOS 
participants (n=137) (-18.5±6.6 kg vs -19.4±5.7 kg, P=0.190). Similarly, the percentage of 
weight loss achieved by both groups was not significantly different (PCOS 17.1%±5.6% vs 
non-PCOS 18.2%±4.4%, P=0.08).
Conclusion: Overall, LighterLife Total could be an effective weight-loss strategy in overweight/
obese women with PCOS. However, further investigations are needed to achieve a thorough 
way of understanding the physiology of weight loss in PCOS.
Keywords: obesity, PCOS, LighterLife, VLCD
Introduction
Polycystic ovary syndrome (PCOS) is one of the most common female endocrine 
disorders, affecting 2%–26% of women of reproductive age (12–45 years old) in the 
UK,1–3 and is suggested to be responsible for up to 75% of cases of infertility caused by 
anovulation.4 While the exact etiology and pathophysiology of PCOS is complicated, 
the resultant hormonal imbalance due to both elevated androgen levels and increased 
insulin secretion in combination with environmental (eg, lifestyle) and genetic factors 
collectively contribute to the etiology of this syndrome.5,6 PCOS has been associated 
with a variety of reproductive and skin disorders and also with an adverse metabolic 
profile including systemic dysfunctions, such as insulin resistance with compensatory 
hyperinsulinemia, hypertension, and dyslipidemia.7,8
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Many studies have reported that there may be a genetic 
susceptibility to the development of PCOS. For example, 
Franks et al9 reported that a genetic polymorphism may be 
responsible for the upregulated insulin metabolism among 
PCOS patients. Moreover, between 50% and 87% of first-
degree relatives of women with PCOS will present with 
some symptoms to varying degrees,10 including but not 
limited to hypertriglyceridemia, hyperinsulinemia, and type 
2 diabetes.11
Increased weight, and central obesity in particular, play 
an important role in the development of PCOS, and as 
such the majority of women with this syndrome are either 
overweight or obese.12–14 Although the exact pathophysi-
ological interactions between excess weight and the clinical 
expression of PCOS remain to be elucidated, it is generally 
acknowledged that obesity itself is an independent risk fac-
tor associated with disturbances in sex-steroid metabolism,15 
insulin resistance,10 and menstrual irregularities.16 Obesity in 
PCOS, however, exacerbates the reproductive, metabolic, 
and psychological effects of excessive weight, and thus 
optimal weight-loss guidelines in the management of PCOS 
are of crucial importance.
Obese women with PCOS face additional barriers in 
achieving weight loss when compared to healthy women 
without this condition. This is postulated to be due to either 
the observed decrease in postprandial thermogenesis,17 
which is also correlated with the degree of reduced insulin 
sensitivity,18 or to specific eating behaviors (eg, emotional 
eating) and snacking patterns (cravings for high-caloric sweet 
and savory snacks) that are observed among overweight/
obese women with PCOS.19 The first-line treatment for PCOS 
includes diet and lifestyle interventions20 to promote a healthy 
weight, especially in cases of overweight and obese patients. 
In these cases, even a modest weight loss of 2%–5% total 
body weight may restore ovulation,21–25 improve the repro-
ductive hormonal profile,24–28 and achieve an improvement 
in insulin sensitivity.23,26–29
There is still, however, much debate over what is consid-
ered to be the optimal weight-loss strategy in PCOS, result-
ing in a lack of evidence-based advice given by dietitians.30 
Interestingly, Jeanes et al31 investigated the dietary recom-
mendations for PCOS patients given by UK dietitians, and 
found little difference from that given to non-PCOS subjects, 
despite the known difficulty among PCOS patients to lose 
weight.
In a systematic review by Nicholson et al,32 the efficacy 
of long-term ($12 months) nonsurgical weight-loss inter-
ventions were presented, and behavioral strategies for obese 
women with PCOS in a systematic review were identified. 
It was concluded that there was not enough evidence to sug-
gest an ideal weight-loss approach in patients with PCOS. 
Although many different dietary approaches have been 
investigated, data on the effectiveness of very low-calorie 
diets (VLCDs) on PCOS are still limited.
A VLCD can be defined as a nutrition plan that provides 
#800 kcal per day,33 and it is comprised of either conventional 
meals or synthetic formulas, eg, shakes, soups, or bars, or a 
combination of both. However, it has been also mentioned by 
Mulholland et al,34 modern VLCDs should not be confused 
with the ones used in the 1970s, the latter being associated 
with several deaths, mainly due to the inclusion of poor-
quality protein and the inadequate provision of vitamins and 
minerals.35,36 Modern commercial VLCDs take into consider-
ation the maintenance of lean body mass by fortification of 
the formulae with high levels of good-quality protein and the 
inclusion of essential electrolytes (sodium, potassium, bicar-
bonate, chloride, calcium, phosphates), fatty acids, minerals, 
and vitamins.37 This approach is safe, and according to the 
National Institute for Health and Care Excellence,38 it can be 
used for up to 3 months continuously for obese patients who 
fail to meet their weight-loss target using a standard low-fat, 
calorie-deficient diet (CDD).
A VLCD can lead to an average weekly weight loss of 
1.5–2.5 kg vs the 0.4–0.5 kg loss achieved with the CDDs.33 
Moreover, the average weight loss at 12 weeks for an obese 
individual is approximately 20 kg on a VLCD, whereas it 
is only 8 kg on a CCD.33 Consequently, a VLCD could be a 
good alternative for obese PCOS patients – both in the short 
and longer term – who may face difficulties losing weight 
despite following standard approaches. For example, Tolino 
et al25 showed that weight loss achieved after 4 weeks of a 
VLCD may lead to a decrease of free testosterone and fast-
ing insulin levels and induce further improvement in men-
struation. Van Dam et al39 carried out an interesting study 
to investigate the effect of short-term dieting in luteinizing 
hormone (LH) homeostasis in obese patients with PCOS. 
According to the observations, both basal and pulsatile secre-
tion of LH were three times higher in PCOS patients when 
compared to matched individual without PCOS, implying 
that caloric restriction failed to normalize the LH secretion. 
On the contrary, total testosterone, glucose, and insulin lev-
els were decreased. In another study, the same researchers40 
examined 15 obese participants with PCOS. Patients were 
studied at baseline (occasion 1), after 1 week of a VLCD 
(occasion 2), and then after achieving 10% weight loss via a 
VLCD (occasion 3). Results suggested that after the weight 
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loss achieved, the estradiol-dependent negative feedback on 
LH was  normalized and led to resumption of ovulation.
Overall, although there is evidence supporting the effi-
cacy of VLCDs, for obese patients who fail to meet their 
weight-loss target using a standard CDD, this approach has 
not been adequately investigated in the area of PCOS, and 
both short- and longer-term data are still needed.
The aim of this retrospective analysis was to assess the 
change in weight in individuals with and without PCOS during 
a 12-week course of a commercial VLCD complemented by a 
group-based behavior-change program (LighterLife Total).
Materials and methods
Source of data
For this retrospective analysis, data were included from women 
aged 18–75 years with body mass index (BMI) $28 kg/m2 
who followed the LighterLife Total approach from  January 
2006 until December 2011. Ethical permission for this 
analysis was obtained from the Robert Gordon University 
Ethics Committee.
Study population
Study participants were self-referred onto the VLCD 
program. Prior to commencement of their weight loss, 
their health and fitness to undertake the weight-loss pro-
gram was assessed using a standardized form provided by 
LighterLife. Participants were excluded from taking part 
in the LighterLife Total program, and consequently from 
the study as well, if they met any of the following criteria: 
type 1 diabetes; porphyria; total lactose intolerance; major 
cardiovascular or cerebrovascular disease; history of renal 
disorder or hepatic disease; active cancer; epilepsy, sei-
zures, convulsions, major depressive disorder, psychotic 
episodes, schizophrenia, bipolar disorders, or delusional 
disorders; current suffering from anorexia, bulimia, or 
undergoing treatment for any other eating disorder; pregnant 
or breastfeeding; had given birth or had a miscarriage in 
the last 3 months.
From a total sample of 102,610 LighterLife participants, 
the PCOS participants (n=508) were matched for age (age ±1 
unit) and BMI (BMI ±1 unit) with the non-PCOS participants 
(n=508) for analysis of 12-week weight-loss data. Baseline 
demographics and 12-week changes in weight and blood 
pressure were compared for the two groups.
Weight-loss program
For those individuals who were eligible, the intervention was 
carried out within a community-based setting. Appointments 
and treatments were managed by lay (but trained behavior-
change) facilitators. The intervention used was a commercial 
weight-management program (LighterLife Total). This is 
a tripartite approach for individuals with BMI $30 kg/m2, 
comprising a VLCD and group support along with behavior 
therapy. The program aims to achieve weight loss and to iden-
tify personal psychological motivation for overconsumption, 
thereby enabling participants to develop robust strategies for 
more successful weight management in the future.
Diet and nutrition
The VLCD provides an average daily intake of 600 kcal 
(50 g protein, 50 g carbohydrate, mean 17 g fat, ie, 36% 
energy from protein, 36% carbohydrate, and 28% fat) in 
the form of food packs (soups, shakes, textured meals, and 
bars) that contain $100% recommended daily allowances 
for vitamins and minerals, including vitamins A, C, D, E, K, 
thiamine, riboflavin, niacin, B
6
, B
12
, folic acid, biotin, pan-
tothenic acid, calcium, phosphorous, iron, zinc, magnesium, 
iodine, potassium, sodium, copper, manganese, selenium, 
molybdenum, chromium, chloride, and fluoride. Clients were 
also able to purchase an ancillary “fiber mix” to add to their 
water, which contained inulin as the source of fiber.
Participants undertook the VLCD alongside a unique 
behavior-change program developed specifically for weight 
management in the obese. This is informed by concepts 
from cognitive behavioral therapy and transactional analysis 
(transactional cognitive behavioral therapy) and addiction/
change theory.41–43 It is delivered in small, single-sex, weekly 
groups by weight-management counselors who are specifi-
cally trained in the facilitation of behavior change for the 
treatment of obesity.
Measurements
Measurements of height and weight took place in Lighter-
Life centers, and were carried out by facilitators who had 
been trained and provided with protocols developed within 
LighterLife. The actual types of equipment used for these 
measurements were not recorded. Measurements were taken 
during weekly meetings that occurred at the same location 
and time each week.
Statistical analysis
Analysis of the individual parameters was performed by the 
use of descriptive statistics, and all variables were assessed 
for normality. Differences of continuous variables between 
groups were assessed using an unpaired two-tailed t-test, 
and differences within groups were assessed using a paired 
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t-test. If more than two groups were compared, analysis of 
variance with a Bonferroni post hoc test was used. For cat-
egorical outcomes, a χ2 analysis was used. All P-values were 
two-sided, and a P-value of 0.05 was considered statistically 
significant. Analyses were performed with SPSS software 
(SPSS Inc., Chicago, IL, USA).
Power
The sample size (508 per group) for this retrospective analy-
sis provided a power greater than 88% to detect a minimum 
difference of 0.2 kg in weight change between the PCOS 
and non-PCOS groups.
Results
The 12-week analysis included both a baseline observation 
carried forward (BOCF) (n=508 for PCOS and n=508 for 
non-PCOS) and a completers (n=137 for PCOS and n=137 
for non-PCOS) analysis.
BOcF analysis
There were no differences between the PCOS and non-
PCOS women in age (34.5±8.2 vs 34.5±8.2 years, P=0.948), 
height (1.65±0.1 m vs 1.65±0.1 m, P=0.937), weight 
(105.4±18.9 kg vs 105.3±19.0 kg, P=0.892), and BMI 
(38.9±6.4 kg/m2 vs 38.8±6.4 kg/m2, P=0.831), as they were 
all matched at  baseline. Weekly weight loss was similar for 
both groups, with no statistically significant differences 
(Figure 1).
After 12 weeks of the VLCD, there was a significant 
weight reduction within each group when compared to base-
line PCOS (105.4±18.9 kg vs 95.0±19.1 kg, P,0.001) and 
non-PCOS (105.3±19.0 kg vs 94.9±19.5 kg, P,0.001). There 
was also a significant change in BMI compared to baseline 
PCOS (38.9±6.4 kg/m2 vs 35.0±6.6 kg/m2, P,0.001) and 
non-PCOS: (38.8±6.4 kg/m2 vs 35.0±6.8 kg/m2, P,0.001). 
Total weight change did not differ significantly between 
the PCOS group and the non-PCOS group (-10.4±10.6 vs 
-10.4±10.4 kg, P=0.938), and both of the groups achieved 
approximately 10% weight loss after the 12-week VLCD 
approach (PCOS -9.7%±9.4% vs non-PCOS -9.7%±9.7%, 
P=0.965).
Table 1 shows the changes in systolic and diastolic blood 
pressure between the PCOS and non-PCOS groups after 
the 12-week VLCD period. As can be seen from the table, 
although the baseline systolic blood pressure was similar for 
both PCOS and non-PCOS participants (PCOS 127.4±12.5 
mmHg vs non-PCOS 127.0±14.0 mmHg, P=0.598), the 
reduction observed after 12 weeks of VLCD was greater 
in the PCOS group (PCOS -5.5±6.1 mmHg vs non-PCOS 
-0.9±6.1 mmHg, P,0.001). With regard to diastolic blood 
pressure, although at baseline women with PCOS had greater 
values than non-PCOS (PCOS 81.5±10.2 mmHg vs non-
PCOS 79.9±9.7 mmHg, P=0.014), after 12 weeks of VLCD 
both groups had similar values (PCOS 80.8±16.1 mmHg vs 
non-PCOS 79.4±9.9 mmHg, P=0.206).
completers analysis
As can be seen in Table 2, there were no differences between 
the PCOS and non-PCOS women in age (35.7±8.9 years vs 
35.8±8.9 years, P=0.946), height (1.65±0.1 m vs 1.64±0.1 m, 
P=0.212), weight (108.3±18.1 kg vs 107.4±19.8 kg, 
P=0.713), or BMI (40.0±6.3 kg/m2 vs 40.0±6.3 kg/m2, 
0
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Figure 1 Weekly weight change for participants with and without PcOS (12-week BOcF, n=508 for each group).
Abbreviations: PcOS, polycystic ovary syndrome; BOcF, baseline observation carried forward.
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P=0.955). Weekly weight loss was similar for both groups, 
with no significant statistical differences (Figure 2).
After 12 weeks of the VLCD, there was a significant 
weight reduction within both groups when compared to base-
line PCOS (108.3±18.1 kg vs 89.8±16.7 kg, P,0.001) and 
non-PCOS (107.4±19.8 kg vs 88.0±17.6 kg, P,0.001). There 
was also a significant change in BMI compared to baseline 
PCOS (40.0±6.4 kg/m2 vs 33.2±6.0 kg/m2, P,0.001) and 
non-PCOS (40.0±6.3 kg/m2 vs 32.8±5.7 kg/m2, P,0.001). 
Total weight change did not differ significantly between the 
PCOS group and the non-PCOS group (-18.5±6.6 kg vs 
-19.4±5.7 kg, P=0.190), and the percentage of weight loss 
achieved by PCOS women was 17.1%±5.6% vs 18.2%±4.4% 
by the non-PCOS group (P=0.08). Moreover, no significant 
differences in weekly weight change between the two groups 
were identified (Figure 2).
Table 3 shows the blood pressure values at baseline and 
after 12 weeks of VLCD. As can be seen from the table, 
baseline systolic blood pressure was lower for the PCOS 
group compared to the non-PCOS group (PCOS 127.2±12.4 
mmHg vs non-PCOS 130.5±13.9 mmHg, P=0.014); how-
ever, there were no differences after 12 weeks of the VLCD 
(PCOS 119.1±13.6 mmHg vs non-PCOS 119.4±13.8 mmHg, 
P=0.800). With regard to diastolic blood pressure, it was 
similar for the PCOS and non-PCOS groups, both at baseline 
(PCOS 81.3±9.8 mmHg vs non-PCOS 80.5±9.6 mmHg, 
P=0.598) and after 12 weeks of the VLCD (PCOS 77.5±11.6 
mmHg vs non-PCOS 74.9±10.2 mmHg, P=0.237).
Discussion
One of the biggest health problems globally is the increasing 
prevalence of obesity. According to the National Infertility 
Group Report,44 half of the women of reproductive age are 
either overweight or obese, and it is known that increased 
weight, and in particular central obesity, plays an important role 
in the development of PCOS.13 Although the first-line treatment 
in overweight and obese women with PCOS is weight loss 
through lifestyle interventions, the complexity and heteroge-
neity of this syndrome in conjunction with the lack of robust 
large scale randomized clinical trials lead to lack of consensus 
over the optimal dietary guidelines to achieve that goal.
In this paper, we attempted to investigate the effect of 
the LighterLife Total VLCD program on weight loss in 
overweight and obese women with PCOS compared to age- 
and BMI-matched non-PCOS participants. It is generally 
proposed that as little as 5% weight loss can improve fertil-
ity outcomes.21–28 In this study, PCOS (completers) achieved 
similar weight reduction with the non-PCOS (completers) 
group, which was more than three times higher than the 
minimum suggested weight loss: 17.1%±5.6% by the 
PCOS vs 18.2%±4.4% by the non-PCOS group (P=0.08) 
after 12 weeks of VLCD in conjunction with group coun-
seling. The BOCF analysis showed more conservative 
results (PCOS -9.7%±9.4% vs non-PCOS -9.7%±9.7%, 
P=0.965), although nevertheless promising. Moreover, in 
both completers and BOCF analysis, women with PCOS 
lost weight at the same rate as non-PCOS women. This 
is in contrast with a number of papers which mentioned 
that women with PCOS may face difficulties in achieving 
weight loss either due to consequent metabolic issues18,19,44 
or the emotional distress that accompanies this disorder, 
and predisposes towards increased energy consumption. 
For example, it has been suggested that women with PCOS 
may have reduced postprandial thermogenesis associated 
with reduced insulin sensitivity, a factor that could influ-
ence the weight loss.18 In addition, adjusted basal meta-
bolic rate appears to be statistically significantly lower in 
women with PCOS, and is more evident in women with 
both PCOS and insulin resistance.45 Interestingly, similar 
observations have been made with regard to patients with 
Table 1 comparison of systolic and diastolic blood pressure 
between the PcOS and non-PcOS participants at baseline and 
12 weeks
Parameter PCOS  
(n=504)
Non-PCOS 
(n=507)
P*
Baseline systolic BP (mmhg) 127.4±12.5 127.0±14.0 0.598
Baseline diastolic BP (mmhg) 81.5±10.2 79.9±9.7 0.014**
Week 12 systolic BP (mmhg) 121.9±20.3 126.1±14.5 0.506
Week 12 diastolic BP (mmhg) 80.8±16.1 79.4±9.9 0.206
change in systolic BP (mmhg) -5.5±6.1 -0.9±6.1 ,0.001***
change in diastolic BP (mmhg) -0.4±5.1 -0.6±4.4 0.517
Notes: *Significance level of the difference between PCOS and non-PCOS groups, 
calculated using an independent t-test; **significant difference between the two groups 
(P,0.05), calculated using an independent t-test; ***P,0.001. Values are means ± 
standard deviation. Week 12 diastolic BP was adjusted for baseline difference using 
analysis of covariance.
Abbreviations: PcOS, polycystic ovary syndrome; BP, blood pressure.
Table 2 comparison of baseline characteristics between PcOS 
(n=137) and matched non-PcOS (n=137)
Parameter PCOS (n=137) Non-PCOS (n=137) P*
age (years) 35.7±8.9 35.8±8.9 0.946
height (m) 1.65±0.1 1.64±0.1 0.212
Weight (kg) 108.3±18.1 107.4±19.8 0.713
BMi (kg/m2) 40.0±6.3 40.0±6.3 0.955
Notes: *Significance level of the difference between PCOS and non-PCOS groups, 
calculated using an independent t-test, calculated using an independent t-test. Values 
are means ± standard deviation.
Abbreviations: PcOS, polycystic ovary syndrome; BMi, body mass index.
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type 2 diabetes.46 Moreover, PCOS patients very often have 
deranged appetite regulation due to reduced postprandial 
cholecystokinin (CCK) secretion compared to control age- 
and BMI-matched individuals without PCOS.47 However, in 
cases where weight reduction was achieved via a ketogenic 
diet, the levels of CCK maintained similar concentrations 
with the ones before the weight loss.48 This could suggest 
that due to the anorexogenic effect of ketosis, the levels 
of CCK were normalised among the PCOS patients, thus 
similar weight loss was achieved between the PCOS and 
non-PCOS group, as also shown by our analysis.
While improvements in weight and BMI have been 
reported by other researchers using variable dietary 
approaches, these lacked a control group,24,49,50 whereas in 
the present study, women without PCOS acted as the control 
group and were also matched for age and BMI for further 
analysis. Moreover, this is the only study in the area of PCOS 
and VLCDs that incorporated the counseling component. 
Although the effect of counseling per se was not assessed, it 
is known that the element of behavioral change not only can 
enhance weight loss but may also improve the completion 
rates of weight-loss programs.51 This support is of extreme 
importance among PCOS patients, where higher incidences 
of depressive and anxiety disorders may predispose them 
toward unhealthy eating behaviors.
Furthermore, several studies have suggested that there is 
an increased prevalence of hypertension among women with 
PCOS compared to the general population, irrespective of 
their weight.52–54 On the other hand, Luque-Ramírez et al55 
support the view that high blood pressure is only observed 
among overweight and obese women with PCOS. In our 
study, women with PCOS presented with higher diastolic 
pressure at baseline, but after 12 weeks of the VLCD, both 
systolic and diastolic pressure were at similar levels with 
their non-PCOS counterparts. This interesting finding could 
imply that in cases of obese women with PCOS, weight loss 
could contribute to normalization of blood pressure levels. 
Nevertheless, further research needs to be done, including 
24-hour ambulatory blood pressure monitoring as well as 
assessment of medication intake and hormonal profile, both 
at baseline and after the end of the VLCD program.
The main strength of the current study is that this is the 
largest investigation to date of a commercial VLCD program, 
LighterLife Total, on weight loss in overweight/obese women 
with PCOS compared to overweight/obese women without 
this syndrome. Although the gold standard in evaluating 
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Figure 2 Weekly weight change for participants with and without PcOS (12-week completers, n=137 for each group).
Abbreviation: PcOS, polycystic ovary syndrome.
Table 3 Values for blood pressure and pulse between the PcOS 
and non-PcOS groups at baseline and 12 weeks
Parameter PCOS Non-PCOS P*
Baseline systolic BP (mmhg) 127.2±12.4 130.5±13.9 0.014**
Baseline diastolic BP (mmhg) 81.3±9.8 80.5±9.6 0.598
Week 12 systolic BP (mmhg) 119.1±13.6 119.4±13.8 0.800
Week 12 diastolic BP (mmhg) 77.5 ±11.6 74.9±10.2 0.237
change in systolic BP (mmhg) -6.8±17.1 -8.7±17.1 0.567
change in diastolic BP (mmhg) -3.9±12.7 -5.6±12.8 0.455
Notes: *Significance level of the difference between PCOS and non-PCOS groups, 
calculated using an independent t-test; **significant difference between the two groups 
(P,0.05), calculated using an independent t-test. For baseline systolic and diastolic 
BP, n=137 for both the PcOS and non-PcOS group. For all the other parameters, 
n=57 for PcOS and n=49 for non-PcOS. Values are means ± standard deviation.
Abbreviations: PcOS, polycystic ovary syndrome; BP, blood pressure.
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health care interventions is carefully designed, conducted, 
and reported randomized controlled trials, our population-
based retrospective analysis assessed the effectiveness of 
a commercial VLCD program in conjunction with weekly 
counseling group sessions, as it runs for real clients who 
joined the LighterLife Total program.
The limitations encountered are mainly attributed to the 
retrospective design of this research. For example, there was 
no information on the criteria used for diagnosis of PCOS, 
and it is highly possible that each of the PCOS women had 
been diagnosed by a different doctor. However, Rolland et al46 
reported that there was no difference in weight loss between 
diabetes and nondiabetes participants when they followed the 
LighterLife Total program, despite the lack of discrepancy in 
relation to diagnosis of type 2 diabetes. Another potential bias 
could be financial status, as only women who can afford the 
weekly costs of this commercial program (approximately £65 
per week) were included. Moreover, due to the small num-
bers encountered in some of the ethnic groups, comparisons 
between the different ethnic categories encountered could 
not be performed. In addition, information on medication 
or potential changes in insulin sensitivity, glycemia, and 
reproductive phenotype was not assessed.
Conclusion
PCOS is a complex condition, with diverse implications 
that include reproductive, metabolic, and psychological 
comorbidities. Its clinical management should focus on lifestyle 
changes with medical therapy when required, as well as provid-
ing patients with support and nutritional education. However, 
evidence-based guidelines are still needed to guide clinicians 
and patients in optimal dietary management of this syndrome. 
The present retrospective analysis suggests that women with 
PCOS lose the same amount of weight and at the same rate 
as non-PCOS women after following a commercial VLCD 
program for 12 weeks in conjunction with group-counseling 
sessions. Consequently, this approach could be considered an 
effective alternative to standard LCDs, especially in cases where 
difficulties in achieving weight loss are encountered.
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